Pharmacology Report: Hypertension Treatment with Medication

This report delves into the pharmacology of hypertension treatment, focusing on the use of various medications. It highlights the role of Enalapril, an angiotensin-converting enzyme inhibitor, and Amlodipine, a calcium channel blocker, in managing blood pressure. The report also discusses the use of Furosemide, a diuretic, and beta-blockers, such as Propranolol, in the context of hypertension. It emphasizes the importance of monitoring blood pressure and considering lifestyle changes, such as dietary adjustments and exercise, in conjunction with medication. Furthermore, it explores the quality use of medication and the potential interactions between different types of drugs, including homeopathic and allopathic medications. The report references relevant studies and research to support its findings, providing a comprehensive overview of hypertension management through pharmacological interventions.

Running head:NURSE PHARMACOLOGY
NURSE PHARMACOLOGY
Name of the student
Name of the university
Author note

1NURSE PHARMACOLOGY
Hypertension is one of the major causes of chronic renal failure due to its adverse
effects on the kidney vasculature due to elevated BP. Enalapril, an angiotensin-converting
enzyme inhibitor, relaxes the blood vessels thus decreasing blood pressure. Furosemide is a
diuretic loop (water pill) stopping too much salt from being consumed by the body (Wang et
al., 2016). Amlodipine is a blocker to the calcium channel that dilates blood vessels and
increases blood flow. Enalapril and amlodipine together have an excellent curative role in the
treatment of aged with hypertension. For elderly patients who seek beta-blockers as
monotherapy or in conjunction with a diuretic thiazide, the incidence of sudden cardiac death
was found to be greater than in patients receiving any form of calcium channel blocker
therapy (Kario & Hoshide, 2015). Propranolol is a beta-blocker that increases noradrenaline
levels, which in turn contributes to the retention of sodium and water.
Since homeopathic drugs are used in extremely diluted doses, they do not interact or
interfere with traditional drug pharmacokinetics or pharmacodynamics, and therefore can be
used along with homeopathic and allopathic drugs.
 BP track for success in the therapy. The reduction in BP is highest after amlodipine
peak levels are reached 6–9 h after oral doses
 Dose-related peripheral or facial edema monitoring for S&S and may not be
accompanied by weight gain; occasionally, extreme edema may cause the medication
to stop.
 Track BP, with changes in posture. Hypotension in the postural study. Most often
checking when adding new antihypertensives or diuretics.
 Track heart rate; palpitations associated with the dose (more common in females) can
occur.
Quality use of medication includes increasing the use of medicinal products, including
prescription, non-prescription, and complementary medicinal products, by health

2NURSE PHARMACOLOGY
practitioners and decision-makers, by customers and the medicinal products industry (Tan et
al., 2017)
Change in lifestyle, reduction in sodium and alcohol, incorporating more fruits,
vegetables, fiber, fish in the diet, adopting DASH eating plan, exercise, losing weight and
avoid taking medication or supplements that contribute to the increase in blood pressure.

3NURSE PHARMACOLOGY
References
Kario, K., & Hoshide, S. (2015). Age-related difference in the sleep pressure-lowering effect
between an angiotensin II receptor blocker and a calcium channel blocker in Asian
hypertensives: the ACS1 Study. Hypertension, 65(4), 729-735.
Tan, C. S., Hassali, M. A., Neoh, C. F., & Saleem, F. (2017). A qualitative exploration of
hypertensive patients’ perception towards quality use of medication and hypertension
management at the community level. Pharmacy Practice (Granada), 15(4).
Wang, X., Wang, G., Shi, J., Aa, J., Comas, R., Liang, Y., & Zhu, H. J. (2016). CES1 genetic
variation affects the activation of angiotensin-converting enzyme inhibitors. The
pharmacogenomics journal, 16(3), 220-230.